Soki Kashima, MD, PhD
About
Titles
Postdoctoral Associate
Biography
Soki Kashima is a urologic surgeon, and a physician-scientist at Akita University School of Medicine in Japan. He graduated from Akita University, and then he received his PhD in Medicine from Akita University Graduate School of Medicine, completing his doctoral research in the Laboratory of Immunology at Kyoto University under the mentorship of Prof. Hiroshi Kawamoto. In doctoral research, he studied the efficacy of antigen-specific T cell therapies derived from iPS cells for renal cell carcinoma, using both in vitro and in vivo (orthotopic xenograft models in mice) models. After his PhD, he has continued his research and clinical work as Assistant Professor at Kyoto University and Akita University with mentorship from Prof. Osamu Ogawa, Prof. Takashi Kobayashi and Prof. Tomonori Habuchi. He has an extensive research skillset in analyzing immune cell function and phenotype, measuring cytotoxicity of T cells, and in patient-derived xenograft mouse models. In the BraunLab, he is using immunogenomic and functional approaches to dissect the tumor microenvironment and understand mechanisms of immunotherapy efficacy in renal cell carcinoma.
Education & Training
- PhD
- Akita University (2020)
- General Exchange Special Research Student
- Institute for Life and Medical Sciences, Kyoto University (2015)
- MD
- Akita University (2011)
Research
Publications
Featured Publications
Update on Biomarkers in Renal Cell Carcinoma.
Saliby R, Saad E, Kashima S, Schoenfeld D, Braun D. Update on Biomarkers in Renal Cell Carcinoma. American Society Of Clinical Oncology Educational Book 2024, 44: e430734. PMID: 38207251, DOI: 10.1200/edbk_430734.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal cell carcinomaCell carcinomaMetastatic renal cell carcinomaTumor intrinsic featuresImmune checkpoint inhibitorsRobust predictive biomarkersCheckpoint inhibitorsDurable responsesOverall survivalCare regimensPathological characteristicsPredictive biomarkersTherapeutic responseTreatment paradigmImmune systemHost factorsTranscriptional signatureGenomic alterationsTumor heterogeneityBiomarkersCarcinomaBiomarker discoveryInnovative technological approachesRegimensThe Changing Landscape of Immunotherapy for Advanced Renal Cancer
Kashima S, Braun D. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urologic Clinics Of North America 2023, 50: 335-349. PMID: 36948676, DOI: 10.1016/j.ucl.2023.01.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaCentral therapeutic strategyAdvanced renal cancerDurable clinical benefitImmune checkpoint inhibitorsImmunecheckpoint inhibitorsCheckpoint inhibitorsCytokine therapyImmunogenic tumorsMost patientsSystemic therapyClinical benefitCombination therapyCurrent therapiesInterleukin-2Renal cancerTherapeutic strategiesTherapyCarcinomaInhibitorsImmunotherapyPatientsInterferonCytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model.
Kashima S, Maeda T, Masuda K, Nagano S, Inoue T, Takeda M, Kono Y, Kobayashi T, Saito S, Higuchi T, Ichise H, Kobayashi Y, Iwaisako K, Terada K, Agata Y, Numakura K, Saito M, Narita S, Yasukawa M, Ogawa O, Habuchi T, Kawamoto H. Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model. IScience 2020, 23: 100998. PMID: 32259478, DOI: 10.1016/j.isci.2020.100998.Peer-Reviewed Original ResearchRegeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes.
Maeda T, Nagano S, Kashima S, Terada K, Agata Y, Ichise H, Ohtaka M, Nakanishi M, Fujiki F, Sugiyama H, Kitawaki T, Kadowaki N, Takaori-Kondo A, Masuda K, Kawamoto H. Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes. Mol Ther Methods Clin Dev 2020, 19: 250-260. PMID: 33102617, DOI: 10.1016/j.omtm.2020.09.011.Peer-Reviewed Original ResearchFaithful preclinical mouse models for better translation to bedside in the field of immuno-oncology.
Saito R, Kobayashi T, Kashima S, Matsumoto K, Ogawa O. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology. Int J Clin Oncol 2020, 25: 831-841. PMID: 31407168, DOI: 10.1007/s10147-019-01520-z.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2024
Prognostic impact of histological discordance between transurethral resection and radical cystectomy.
Matsuda A, Taoka R, Miki J, Saito R, Fukuokaya W, Hatakeyama S, Kawahara T, Fujii Y, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Iio H, Yasue K, Abe T, Nakanishi S, Matsumura M, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Matsui Y, Japanese Urological Oncology Group. Prognostic impact of histological discordance between transurethral resection and radical cystectomy. BJU Int 2024 PMID: 38344879, DOI: 10.1111/bju.16296.Peer-Reviewed Original Research
2023
Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.
Kobayashi M, Numakura K, Hatakeyama S, Ishida T, Koizumi A, Tadachi K, Igarashi R, Takayama K, Muto Y, Sekine Y, Sobu R, Sasagawa H, Akashi H, Kashima S, Yamamoto R, Nara T, Saito M, Narita S, Ohyama C, Habuchi T. Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old. Int J Clin Oncol 2023, 28: 1530-1537. PMID: 37552353, DOI: 10.1007/s10147-023-02394-y.Peer-Reviewed Original ResearchPrimary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.
Numakura K, Sekine Y, Hatakeyama S, Muto Y, Sobu R, Kobayashi M, Sasagawa H, Kashima S, Yamamto R, Nara T, Akashi H, Tabata R, Sato S, Saito M, Narita S, Ohyama C, Habuchi T. Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma. Cancer Med 2023, 12: 16837-16845. PMID: 37403728, DOI: 10.1002/cam4.6306.Peer-Reviewed Original ResearchImpact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate.
Takahashi Y, Narita S, Shiota M, Miura M, Kagaya H, Kashima S, Yamamoto R, Nara T, Huang M, Numakura K, Saito M, Eto M, Habuchi T. Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate. Eur J Clin Pharmacol 2023, 79: 89-98. PMID: 36378297, DOI: 10.1007/s00228-022-03420-0.Peer-Reviewed Original ResearchASCO 2023 RECAP Combination Therapies Come of Age in Kidney Cancer
https://auanews.net/issues/articles/2023/october-extra-2023/asco-2023-recap-combination-therapies-come-of-age-in-kidney-cancerBooks